Sindrom Kavasaki u detey: obzor literatury i analiz 22 sobstvennykh nablyudeniy


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Kawasaki syndrome (KS) is an acute multisystem disease of unknown etiology with the development of vasculitis. For the evaluation of clinical manifestations and assessment of effectiveness of treatment, 22 patients with KS aged 2.5 months to 12 years were examined and treated. Among children hospitalized during first 10 days of illness, 25% of cases were diagnosed with partial KS; three children were diagnosed with KS only after the appearance of new symptoms and / or ineffectiveness of antibacterial therapy. In 70% of cases, the diagnosis was not in doubt on admission, as well as in case of hospitalization 10 days after onset. Single dose (2 g/kg) of intravenous immunoglobulin was effective in 77% of patients; booster dose had to be administered in 23% of cases. In young children, prolonged fever of unknown etiology requires constant awareness with regard to the KS, in order to begin specific treatment during first 10 days of illness to prevent the development of coronary artery aneurysms.

Full Text

Restricted Access

References

  1. The Merck Manual. Руководство по медицине. Диагностика и лечение. М., 2011.
  2. Лыскина Г.А., Ширинская О.Г. Слизистокожный лимфонодулярный синдром (синдром Кавасаки). Диагностика и лечение. М., 2008. 144 с.
  3. Yanagawa H., Nakamura Y., Yashiro M., Oki I., Hirata S., Zhang T., Kawasaki T. Incidence survey of Kawasaki disease in 1997 and 1998 in Japan. Pediatrics. 2001;107(3).
  4. Burns J.C. The riddle of Kawasaki disease. N. Engl. J. Med. 2007;356:659-61.
  5. Kliegman R.M., Stanton B.F., Joseph Geme W.St., Schor N.F., Behrman R.E. Nelson textbook of pediatrics. Elsevier saunders, 19-th ed., 2011.
  6. Holman R.C., Belay E.D., Christensen K.Y., Folkema A.M., Steiner C.A., Schonberger L.B. Hospitalizations for Kawasaki syndrome among children in the United States, 1997-2007. Pediatric Infect. Dis. J. 2010;2:483-88.
  7. Брегель Л.В., Солдатова Т.А., Субботин В.М., Кавасаки Т., Янагава Х., Сузуки А., Бойко Т.В., Голенецкая Е.С. Эпидемиологические особенности болезни Кавасаки в России и Японии. Тезисы VII Всероссийского конгресса по детской кардиологии. М., 2012.
  8. Лыскина Г.А., Виноградова О.И., Ширинская О.Г., Брегель Л.В., Субботин В.М., Бернс Джейн. Клиника, диагностика и лечение синдрома Кавасаки. Клинические рекомендации. М., 2011.
  9. Rodо X., Ballester J., Cayan D., Melish M.E., Nakamura Y., Uehara R., Burns J.C. Association of Kawasaki disease with tropospheric wind patterns. Scientific Reports. 2011;152.
  10. Newburger J.W.,Takahashi M., Gerber M.A., Gewitz M.H., Tani L.Y., Burns J.C., Shulman S.T., BolgerA.F.,FerrieriP., BaltimoreR.S.,WilsonW.R., Baddour L.M., Levison M.E., Pallasch T.J., Falace D.A.,Taubert K.A. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Statement for Health Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics. 2004;114:1708.
  11. Логинова М.С., Брегель Л.В., Субботин В.М. Кардиальные проявления болезни Кавасаки. Тезисы VII Всероссийского конгресса по детской кардиологии. М., 2012.
  12. Kato H.,Sugimura T.,Akagi T.,Sato N., Hashino K., Maeno Y., Kazue T., Eto G., Yamakawa R. Longterm consequences of Kawasaki disease. A 10-to 21 year follow-up study of 594 patients. Circulation. 1996;94:1379-85.
  13. Freeman A.F., Crawford S.E., Finn L.S., LopezAndreu J.A., Ferrando-Monleon S., Perez-Tamarit D., Cornwall M.L., Shulman S.T., Rowley A.H. Inflammatory pulmonary nodules in Kawasaki disease. Pediatr. Pulmonology. 2003; 36:102-06.
  14. Uziel Y., Hashkes P.J., Kassem E., Gottesman G., Wolach B. «Unresolving pneumonia» as the main manifestation of atypical Kawasaki disease. Arch. Dis. Child. 2003;88:940-42.
  15. Palazzi D.L., McClain K.L., Kaplan S.L. Hemophagocytic syndrome after Kawasaki disease. Pediatr. Infect. Dis. 2003;22:663-66.
  16. Sundel R.P., Cleveland S.S., Beiser A.S., Newburger J.W., McGill T., Baker A.L., Koren G., Novak R.E., Harris J.P., Burns J.C. Audiologic profiles of children with Kawasaki disease. Am. J. Otol. 1992;13:512-15.
  17. Knott P.D., Orloff L.A., Harris J.P., Novak R.E., Burns J.C.; Kawasaki Disease Multicenter Hearing Loss Study Group. Sensorineural hearing loss and Kawasaki disease: a prospective study. Am. J. Otolaryngol. 2001;22: 343-48.
  18. Брегель Л.В., Субботин В.М., Никитина Е.А. Коронарные осложнения и нарушения в системе гемостаза при болезни Кавасаки. Российский вестник перинаталогии и педиатрии. 2004;17:9.
  19. Ting E.C., Capparelli E.V., Billman G.F., Lavine J.E., Matsubara T., Burns J.C. Elevated gamma-glutamyltransferase concentrations in patients with acute Kawasaki disease. Pediatr. Infect. Dis.1998;17:431-32.
  20. Kentsis A., Shulman A., Ahmed S., Brennan E., Monuteaux M.C., Lee Y.H., Lipsett S., Paulo J.A., Dedeoglu F., Fuhlbrigge R., Bachur R., Bradwin G., Arditi M., Sundel R.P., Newburger J.W., Steen H., Kim S. Urine proteomics for discovery of improved diagnostic markers of Kawasaki disease. EMBO Mol. Med. 2013;5(2):210-20.
  21. Kato H., Kanematsu M., Kato Z., Teramoto T., Kondo N., Hoshi H. Computed tomographic findings of Kawasaki disease with cervical lymphadenopathy. J. Comput. Assist Tomogr. 2012;36(1):138-42.
  22. Баранов А.А., Таточенко В.К., Бакрадзе М.Д. Лихорадочные синдромы у детей. Рекомендации по диагностике и лечению. М., 2011. 211 с.
  23. Terai M., Shulman S.T. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J. Pediatr. 1997;131:888-93.
  24. Williams R.V., Minich L.L., Tani L.Y. Pharmacological therapy for patients with Kawasaki disease. Pediatr. Drugs. 2001; 3:649-60.
  25. Tremolet A.H., Jain S., Jaggi P., Jimenez-FernandezS., PancheriJ.M., Sun X., KanegayeJ.T., Kovalchin J.P., Printz B.F., Ramilo O., Burns J.C. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet. 2014;383(9930):1731-38.
  26. Chen S., Dong Y., Yin Y., Krucoff M.W. Intravenous Immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease. Heart. 2013;99:76-82.
  27. Moffett B.S., Syblik D., Denfield S., Altman C., Tejtel-Sexson K. Epidemiology of immunoglobulin resistant kawasaki disease: results from a large, national database. Pediatr. Cardiol. 2015; 36(2):374-78.
  28. Holve T.J., Patel A., Chau Q., Marks A.R., Meadows A., Zaroff J.G. Long-term cardiovascular outcomes in survivors of Kawasaki disease. Pediatrics. 2014;133(2):305-11.
  29. Broderick L., Tremoulet A.H., Burns J.C., Bastian J.F., Hal M. Reccurent fever syndromes in patients after recovery from Kawasaki syndrome. Pediatrics. 2011:127.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Bionika Media